Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7509518 | 0.93 | TLR8 (0.62) | TLR8TLR7 | |
| SCHEMBL7515942 | 0.90 | TLR8 (0.55) | TLR8TLR7 | |
| SCHEMBL22783822 | 0.88 | TLR8 (0.67) | TLR8TLR7 | |
| SCHEMBL10044370 | 0.86 | TLR8 (0.73) | TLR8TLR7 | |
| SCHEMBL21841760 | 0.85 | TLR8 (0.76) | TLR8TLR7 | |
| SCHEMBL1239780 | 0.85 | TLR8 (0.69) | TLR8TLR7 | |
| SCHEMBL28809627 | 0.84 | TLR8 (0.51) | TLR8TLR7 | |
| SCHEMBL31506966 | 0.84 | TLR8 (0.51) | TLR8TLR7 | |
| SCHEMBL20492597 | 0.84 | TLR8 (0.76) | TLR8TLR7 | |
| SCHEMBL8189364 | 0.84 | TLR8 (0.74) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145575-A1 | MACROMOLECULE-SUPPORTED 8-SULFONYL-BENZAZEPINE COMPOUNDS AND THEIR USES | BOLT BIOTHERAPEUTICS, INC. (US) | 2025-05-08 | — | — | US | disclosed |
| US-20250127914-A1 | ANTIBODY-CONJUGATED 8-SULFONYL-BENZAZEPINE COMPOUNDS AND THEIR USES | BOLT BIOTHERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| EP-0825186-B1 | 2-Aminobenzazepine derivatives and their use for the treatment of immunosuppression | PFIZER (US) | 2002-04-17 | — | — | EP | disclosed |
| US-6043238-A | 2-Aminobenzazapine derivatives | PFIZER INC. (US) | 2000-03-28 | — | — | US | disclosed |
| EP-0825186-A1 | 2-Aminobenzazepine derivatives and their use for the treatment of immunosuppression | PFIZER INC. (US) | 1998-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145575-A1 | MACROMOLECULE-SUPPORTED 8-SULFONYL-BENZAZEPINE COMPOUNDS AND THEIR USES | BRD4, MUS81, ABCC8 | TLR8 1341/4885TLR7 3140/4885 |
| US-20250127914-A1 | ANTIBODY-CONJUGATED 8-SULFONYL-BENZAZEPINE COMPOUNDS AND THEIR USES | BCR, CD22, IGSF11 | TLR8 851/4885TLR7 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.